About Yocon

To make contributions to the improvement of the human life and health.

Yocon Biology Technology Company

Founded in 2006, YOCON is a leading R&D service supplier of serum-free cell culture products and molecular diagnostic products in China. It is committed to producing high-quality and brand serum-free cell culture products, laying a solid foundation for cell therapy products. YOCON has 7 invention patents, 12 utility model patents, 1 registration certificate for Class II in vitro reagents, 24 filing certificates for Class I medical devices, and 5 software copyrights. It is qualified as a Zhongguancun high-tech enterprise and a national high-tech enterprise, having passed ISO9001 and ISO13485 certifications. The company is headquartered in Haidian District, Beijing, with offices in Shanghai, Guangzhou, etc.

After more than ten years of development, YOCON has customers such as CDCs, scientific research institutions in universities, industrial enterprises, and clinical hospitals. YOCON serum-free cell culture products are mainly used for mesenchymal stem cells, immune cells, and cell therapy accessory reagents, which are developed to provide customers with a safe and convenient culture. The medium for mesenchymal stem cells has the leading performance and has been accepted by the US Food Drug Administration for registration, which is the first in China. YOCON Biology also carries out business cooperation with many enterprises declaring cellular drugs.

Its molecular diagnostic products are mainly used for sample collection, extraction, and testing in CDCs, hospitals, customs, etc. After the outbreak of COVID-19, YOCON virus sampling products are available as rare products registered under Class II medical devices in China. The company has become one of the key government-appointed enterprises for epidemic prevention and control. Thanks to their excellent performance. YOCON virus sampling kits have passed product testing in North America, South America, Australia, and the Middle East becoming government-appointed products in Canada and Australia. During COVID-19, YOCON has not forgotten its social responsibility, and up to now, we have donated virus sampling products valued at more than RMB 20.00 million, thus making great contributions to domestic and international virus detection.

In 2021, YOCON successfully developed the FE4800 automatic nucleic acid extraction and purification instrument, achieving a technological breakthrough, including automatic, systematic, and customized unification and upgrade of multiple steps of nucleic acid extraction, with 6 product patents and 4 software copyrights, marking the formal initiation of R&D and production of YOCON molecular diagnosis and cell therapy products.

YOCON will continue to increase its R&D efforts, expand the area used for R&D, and strengthen the construction of the R&D team. The new R&D and production base of YOCON in Miyun District, Beijing, China covering a construction area of about 42,000 m2, is listed as a 2021 key project in Beijing and will be put into operation in the future. The production base will meet the regulatory requirements of NMPA, CE, and the US Food and Drug Administration. YOCON will provide more high-quality and innovative molecular diagnostic and cell therapy products for customers at home and abroad.

The staff of YOCON will always keep their original intention and forge ahead to open a new era in the fields of cell therapy and molecular diagnosis!